NovoCure (NVCR) director sells 2,945 shares in tax-related trade

Rhea-AI Filing Summary

NovoCure Ltd director Jeryl L. Hilleman reported a mandated sale of 2,945 ordinary shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share.

According to the disclosure, the sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. After this transaction, Hilleman directly holds 13,861 ordinary shares of NovoCure.

Insider Trade Summary

Net Seller: 2,945 shares ($46,445)

Net Sell 1 txn

Insider HILLEMAN JERYL L

Role null

Sold 2,945 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	2,945	$15.7707	$46K

Holdings After Transaction: Ordinary Shares — 13,861 shares (Direct, null)

Footnotes (1)

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.

Key Figures

Shares sold: 2,945 shares Weighted average sale price: $15.7707 per share Post-transaction holdings: 13,861 shares +1 more

4 metrics

Shares sold 2,945 shares Ordinary shares sold on June 2, 2026

Weighted average sale price $15.7707 per share Open-market sale on June 2, 2026

Post-transaction holdings 13,861 shares Direct ownership after sale

Sale price range $15.65–$15.88 per share Multiple trades within this range

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"funded by a "sell to cover" transaction and does not represent"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"under its equity incentive plans to require the satisfaction"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HILLEMAN JERYL L

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/02/2026		S		2,945(1)	D	$15.7707(2)	13,861	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Hilleman, Jeryl L.	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NovoCure (NVCR) director Jeryl Hilleman report?

NovoCure (NVCR) director Jeryl L. Hilleman reported selling 2,945 ordinary shares. The transaction occurred on June 2, 2026 as part of a mandated sale to cover tax obligations related to the vesting of Restricted Stock Units under the company’s equity incentive plans.

Why did Jeryl Hilleman sell NovoCure (NVCR) shares on June 2, 2026?

The sale was executed to cover tax withholding obligations from the vesting of Restricted Stock Units. NovoCure’s award agreement requires these obligations to be funded through a mandatory “sell to cover” transaction, so the trade was not a discretionary decision by Hilleman.

How many NovoCure (NVCR) shares does Jeryl Hilleman hold after the reported sale?

Following the transaction, Jeryl L. Hilleman directly holds 13,861 ordinary shares of NovoCure (NVCR). This figure reflects the ownership position after the mandated sale of 2,945 shares to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units.

At what prices were Jeryl Hilleman’s NovoCure (NVCR) shares sold?

The reported weighted average sale price was $15.7707 per share. A footnote explains the transaction was executed in multiple trades at prices ranging from $15.65 to $15.88 per share, all completed on June 2, 2026, in the open market.

Was Jeryl Hilleman’s NovoCure (NVCR) share sale a discretionary trade?

No. The filing states the sale was mandated by NovoCure’s award agreement under its equity incentive plans. It was executed as a “sell to cover” transaction solely to fund tax withholding obligations and is characterized as not a discretionary trade by Hilleman.